At 52 weeks , 30.9 % of the combination therapy group achieved prolonged and 36.6 % achieved 7-day point-prevalence smoking abstinence compared with 24.5 % and 29.2 % in varenicline monotherapy ( OR , 1.39 ; 95 % CI , 0.93-2 .07 ; P = .11 and OR , 1.40 ; 95 % CI , 0.96-2 .05 ; P = .08 , respectively ) .